Get the Facts
How PBMs Reduce the Cost of High-priced Drugs

Fact: PBMs are leveraging competition and driving deep discounts on high-priced drugs for consumers, employers, unions, and government programs. A recent study showed that PBMs negotiated better discounts on expensive hepatitis C medications than most European, price-controlled countries.

  • Costs for hepatitis C drugs were nearly cut in half when new brand competitors entered the marketplace. When there is real competition in the market, PBMs can negotiate rebates and discounts that lower prescription drug costs for consumers.

     

  • A new study debunks the notion that the prices drugmakers set are contingent on the rebates they negotiate with PBMs. Ironically, many higher priced drugs involve little or no such rebates. 

Pharmacy Benefit Managers: Part of the solution to high drug prices

As policymakers consider new ways to reduce prescription drug costs, they should start by rejecting schemes to undercut the cost-savings tools widely used by employers, unions, health plans, and popular, affordable programs like Medicare Part D. Specifically, lawmakers must protect the ability of the employers...

PBMs: Protecting Consumers and Employers From High Drug Prices

The competition-based PBM approach has been highly successful, yielding broad access to prescription drugs and 90% consumer satisfaction rates. A recent study shows PBMs are on track to reduce prescription drug coverage costs by $654 billion over the next decade for government and commercial payers.

American Action Forum: The Donald has Spoken

The reality is that the president cannot use government negotiations to lower drug prices. Despite the repeated assertions to the contrary, there are tons of negotiations in the Medicare drug program. They are private negotiations between and among prescription drug plans, pharmacy benefit managers, and...